Chief Business Officer appointed at Accession Therapeutics as company prepares for clinical trials

Accession Therapeutics presented some of the exciting preclinical data for our lead programme

Biocentury Emerging Company Profile  -  Accession: precisely targeted oncolytic viruses

Accession Therapeutics is attending the J.P. Morgan 41st Annual Healthcare Conference - January 2023

Accession Therapeutics raises £16.6m to advance potent immunotherapies towards clinical trials

Cancer leader Professor Alan Parker joins Accession Therapeutics

Bent Jakobsen starts novel immune-oncology firm Accession Therapeutics